KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Total Liabilities (2016 - 2025)

Eli Lilly's Total Liabilities history spans 17 years, with the latest figure at $85.9 billion for Q4 2025.

  • For Q4 2025, Total Liabilities rose 33.36% year-over-year to $85.9 billion; the TTM value through Dec 2025 reached $85.9 billion, up 33.36%, while the annual FY2025 figure was $85.9 billion, 33.36% up from the prior year.
  • Total Liabilities reached $85.9 billion in Q4 2025 per LLY's latest filing, down from $91.1 billion in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $104.6 billion in Q2 2025 to a low of $38.5 billion in Q2 2022.
  • Average Total Liabilities over 5 years is $63.6 billion, with a median of $55.8 billion recorded in 2023.
  • Peak YoY movement for Total Liabilities: fell 19.44% in 2022, then surged 49.03% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $51.4 billion in 2021, then grew by 2.17% to $52.5 billion in 2022, then grew by 25.37% to $65.8 billion in 2023, then fell by 2.1% to $64.4 billion in 2024, then soared by 33.36% to $85.9 billion in 2025.
  • Per Business Quant, the three most recent readings for LLY's Total Liabilities are $85.9 billion (Q4 2025), $91.1 billion (Q3 2025), and $104.6 billion (Q2 2025).